Document is current
Any future updates will be listed below
-
Authors
Leonhard, Sonja E. https://orcid.org/0000-0003-4832-6926
Papri, Nowshin
Querol, Luis https://orcid.org/0000-0002-4289-8264
Rinaldi, Simon
Shahrizaila, Nortina
Jacobs, Bart C. https://orcid.org/0000-0002-8985-2458
- License Information
-
More Information
Article History
Accepted: 13 November 2024
First Online: 19 December 2024
Competing interests
: S.E.L. declares no competing interests. N.P. declares no competing interests. N.S. declares no competing interests. S.R. reports institutional funding for research related to Guillain–Barré syndrome (GBS) from the Wellcome Trust, Medical Research Council (UK) and GBS-CIDP Foundation International. He has undertaken consultancies for argenx, Hansa Biopharma, Dainthus and Annexon related to the treatment of inflammatory neuropathies. He is a member of the IGOS biobank committee and of the Medical Advisory Board of the GBS and related inflammatory neuropathies (GAIN) patient support group. L.Q. received research grants from Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain), CIBERER, Fundació La Marató, GBS-CIDP Foundation International, UCB, argenx and Grifols. L.Q. received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi Genzyme, Merck, Annexon, Alnylam, Janssen, argenx, UCB, Dianthus, LFB, Avilar Therapeutics, Nuvig Therapeutics, Takeda and Roche. L.Q. serves at the Clinical Trial Steering Committees for Sanofi Genzyme and argenx, and was Principal Investigator for UCB’s CIDP01 trial. L.Q. is a member of the Steering Committee of IGOS. B.C.J. reports institutional funding for research related to GBS from Prinses Beatrix Spierfonds, Zon-MW, GBS-CIDP Foundation International, Horizon 2020, Grifols, CSL Behring, Annexon, Roche and Hansa Biopharma. B.C.J. is in the Clinical Trial Committee of Annexon. B.C.J. serves as the chair of the Steering Committee of IGOS and is a member of the Global Medical Advisory Board of the GBS-CIDP Foundation International.
